U.K.-based SkyePharma's Flutiform, an inhaled combination of fluticasone and formoterol, has been launched in Germany by the company's partner, Mundipharma, as an asthma maintenance therapy.

DUBLIN--(BUSINESS WIRE)--The "Drug Overview: Flutiform" report has been added to ResearchAndMarkets.com's offering. Flutiform ([fluticasone propionate + formoterol fumarate]; ...

LONDON (MarketWatch) -- U.K. drug delivery company SkyePharma PLC Tuesday said it has signed a deal with Kyorin Co. Ltd. (4569.TO) to develop and distribute its key experimental product, asthma ...

LONDON, UK, 1 September 2009 - SkyePharma PLC (LSE: SKP) today provides an update following a meeting held with the US Food and Drug Administration (FDA) to discuss the previously announced potential ...

Respiratory player Vectura can set aside its hopes of snagging a new COPD indication for its combination med Flutiform--at least for now. Tuesday, the U.K. company said that its ICS/LABA med had ...

SkyePharma’s shares were given a hefty boost yesterday after the company announced that a late-stage trial of Flutiform was a success, paving the way for the drug’s filing in Europe during the first ...

Vectura said today that its marketed asthma drug flutiform ® has failed a Phase III trial intended to support an additional indication in Europe of chronic obstructive pulmonary disease (COPD).

flutiform® receives positive opinion in Europe for the Treatment of Children with Asthma Mundipharma's combination treatment will soon be available in Europe as a maintenance treatment for asthma in ...

British drugmaker Vectura reported a doubling in first-half losses and warned full-year revenues would be hit by customers running down stocks of asthma inhaler Flutiform, sending its shares as much ...

(Reuters) - British drugmaker Vectura said its asthma inhaler Flutiform had made favourable regulatory progress in Europe, and it can now apply for approvals through its partner. Vectura said its ...